Literature DB >> 23749108

Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.

S Akhtar1, A S Al-Sugair, M Abouzied, Y Alkadhi, M Dingle, M Abdelsalam, H Soudy, A Darwish, A Eltigani, T A M Elhassan, M Nabil-Ahmed, I Maghfoor.   

Abstract

Hodgkin's lymphoma (HL) patients with positive (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) post salvage chemotherapy or before high-dose chemotherapy and auto-SCT (HDC ASCT) have inferior outcomes. We reviewed 21 prognostic factors before salvage chemotherapy (at relapse/progression) and integrated post salvage FDG-PET results to develop a prognostic model for post HDC ASCT outcome. We used Fine and Gray method for competing risk analysis and regression model for risks assessment and outcome. One hundred and forty-one patients had post salvage FDG-PET before HDC ASCT (median age 25.5 years); male/female 55%:45%, relapsed/refractory 43%:57%, median follow-up 33 months. Multivariate analysis identified HL International Prognostic Score 3 (P=0.001; hazard ratio (HR): 3.7 (1.6-8.3)) and post salvage positive FDG-PET (P=0.011; HR: 3.4 (1.3-8.9)) with higher hazard of disease-specific death (model P=0.0001). Cumulative incidence of disease-specific death with 0, 1, 2 risk factors was 7%:29%:52%, respectively (P=0.00003). For disease-specific event (persistent, progressive or relapsed disease), mediastinal involvement (P=0.024; HR: 2.7 (1.14-6.5)), B symptoms (P=0.027; HR: 2.1 (1.09-4.2)) and positive post salvage FDG-PET (P=0.001; HR: 3.3 (1.7-6.7)) were significant (model P=<0.00001). Cumulative incidence of disease-specific event with 0, 1, 2, 3 risk factors was 8%:31%:50%:75%, respectively (P=0.0000006). Patients with higher scores have higher risk of treatment failure. They are potential candidates for newer therapies along with HDC ASCT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749108     DOI: 10.1038/bmt.2013.88

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

Review 1.  Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

Authors:  Alison J Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

Authors:  M A Kharfan-Dabaja; M Hamadani; H Sibai; B N Savani
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

Review 3.  Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

Authors:  Niloufer Khan; Alison J Moskowitz
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

4.  High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.

Authors:  Muhammad Shahzad Rauf; Irfan Maghfoor; Tusneem Ahmed M Elhassan; Saad Akhtar
Journal:  Med Oncol       Date:  2014-11-28       Impact factor: 3.064

5.  Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

Authors:  Matthew G Mei; Hun Ju Lee; Joycelynne M Palmer; Robert Chen; Ni-Chun Tsai; Lu Chen; Kathryn McBride; D Lynne Smith; Ivana Melgar; Joo Y Song; Kimberley-Jane Bonjoc; Saro Armenian; Mary Nwangwu; Peter P Lee; Jasmine Zain; Liana Nikolaenko; Leslie Popplewell; Auayporn Nademanee; Ammar Chaudhry; Steven Rosen; Larry Kwak; Stephen J Forman; Alex F Herrera
Journal:  Blood       Date:  2022-06-23       Impact factor: 25.476

6.  Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.

Authors:  Gunjan L Shah; Joachim Yahalom; Matthew J Matasar; Stephanie L Verwys; Debra A Goldman; Kurt S Bantilan; Zhigang Zhang; Susan J McCall; Alison J Moskowitz; Craig H Moskowitz
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

7.  Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.

Authors:  Reid W Merryman; Robert A Redd; Taiga Nishihori; Julio Chavez; Yago Nieto; Justin M Darrah; Uttam Rao; Michael T Byrne; David A Bond; Kami J Maddocks; Michael A Spinner; Ranjana H Advani; Hatcher J Ballard; Jakub Svoboda; Anurag K Singh; Joseph P McGuirk; Dipenkumar Modi; Radhakrishnan Ramchandren; Jason Romancik; Jonathon B Cohen; Matthew J Frigault; Yi-Bin Chen; Anthony V Serritella; Justine Kline; Stephen Ansell; Sunita Nathan; Maryam Rahimian; Robin M Joyce; Mansi Shah; Kevin A David; Steven Park; Anne W Beaven; Alma Habib; Veronika Bachanova; Shazia Nakhoda; Nadia Khan; Ryan C Lynch; Stephen D Smith; Vincent T Ho; Ann LaCasce; Philippe Armand; Alex F Herrera
Journal:  Blood Adv       Date:  2021-03-23

8.  A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.

Authors:  P Satwani; K W Ahn; J Carreras; H Abdel-Azim; M S Cairo; A Cashen; A I Chen; J B Cohen; L J Costa; C Dandoy; T S Fenske; C O Freytes; S Ganguly; R P Gale; N Ghosh; M S Hertzberg; R J Hayashi; R T Kamble; A S Kanate; A Keating; M A Kharfan-Dabaja; H M Lazarus; D I Marks; T Nishihori; R F Olsson; T D Prestidge; J M Rolon; B N Savani; J M Vose; W A Wood; D J Inwards; V Bachanova; S M Smith; D G Maloney; A Sureda; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2015-08-03       Impact factor: 5.483

9.  Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.

Authors:  Maurizio Musso; Giuseppe Messina; Nicola Di Renzo; Paolo Di Carlo; Umberto Vitolo; Renato Scalone; Gianpaolo Marcacci; Potito R Scalzulli; Tiziana Moscato; Rossella Matera; Alessandra Crescimanno; Stella Santarone; Enrico Orciuolo; Anxur Merenda; Vincenzo Pavone; Domenico Pastore; Daniela Donnarumma; Angelo M Carella; Chiara Ciochetto; Nicola Cascavilla; Anna Mele; Francesco Lanza; Massimo Di Nicola; Erminio Bonizzoni; Antonello Pinto
Journal:  Br J Haematol       Date:  2015-10-12       Impact factor: 6.998

Review 10.  Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Ann Hematol       Date:  2016-03-02       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.